Forma de presentación | 14 JUN 06
Revisión del síndrome del glucagonoma
El eritema migratorio necrolítico es la forma de presentación de casi el 70% de los glucagonomas.
Autor/a: Andre P van Beek, Ellen R M de Haas, Willem A van Vloten, Cees J M Lips, Janine F M Roijers and Mari Archives of Dermatology and Syphilology 1942 45 1069–1080.
Desarrollo
1. 1 Becker SW, Kahn D & Rothman S. Cutaneous manifestations of internal malignant tumors. Archives of Dermatology and Syphilology 1942 45 1069–1080.
2. 2 McGavran MH, Unger RH & Recant L. A glucagon-secreting alpha-cell carcinoma of the pancreas. New England Journal of Medicine 1966 274 1408–1413.
3. 3 Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Transactions of the St John’s Hospital Dermatological Society 1973 59 244–250.
4. 4 Wilkinson DS. Necrolytic migratory erythema with pancreatic carcinoma. Proceedings of the Royal Society of Medicine 1971 64 1197.
5. 5 Wermers RA, Fatourechi V, Wynne AG, Kvols LK & Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996 75 53–63.
6. 6 Edney JA, Hofmann S, Thompson JS & Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. American Journal of Surgery 1990 160 625–628.
7. 7 Wermers RA, Fatourechi V & Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clinic Proceedings 1996 71 1030–1038.
8. 8 Akerstrom G, Hessman O & Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Archives of Surgery 2002 386 558–569.
9. 9 Geerdink E, Van der Luijt RB & Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? European Journal of Endocrinology 2003 149 577–582.
10. 10 Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocrine Reviews 1981 2 347–361.
11. 11 Rosenberg PM & Goldfinger SE. Glucagonoma and the glucagonoma syndrome. In UptoDate 2004 online 11.3.
12. 12 Nightingale KJ, Davies MG & Kingsnorth AN. Glucagonoma syndrome: survival 24 years following diagnosis. Digestive Surgery 1999 16 68–71.
13. 13 Altimari AF, Bhoopalam N, O’Dorsio T, Lange CL, Sandberg L & Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986 100 989–996.
14. 14 Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO &Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa,
15. and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003 21 2689–2696.
16. 15 Alexander EK, Robinson M, Staniec M & Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clinical Endocrinology 2002 57 827–831.
17. 16 Bewley AP, Ross JS, Bunker CB & Staughton RC. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. British Journal of Dermatology 1996 134 1101–1104.
18. 17 Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. American Journal of the Medical Sciences 2001 321 306–320.
19. 18 Binnick AN, Spencer SK, Dennison WL Jr & Horton ES. Glucagonoma syndrome. Report of two cases and literature review. Archives of Dermatology 1977 113 749–754.
20. 19 Haneke E. Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy. Zeitschrift fur Hautkrankheiten 1984 59 902–908.
21. 20 Hoitsma HF, Cuesta MA, Starink TM, Uttendorfsky-van der Putten HJ & van der Veen EA. Zinc deficiency syndrome versus glucagonoma syndrome. Archivum Chirurgicum Neerlandicum 1979 31 131–140.
22. 21 El Darouti M & Abu eE. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. International Journal of Dermatology 1996 35 252–256.
23. 22 Hendricks WM. Pellagra and pellagra like dermatoses: etiology, differential diagnosis, dermatopathology, and treatment. Seminars in Dermatology 1991 10 282–292.
24. 23 Stratigos JD & Katsambas AD. Pellagra: ‘A reappraisal’. Acta Vitaminologica et Enzymologica 1982 4 115–121.
25. 24 Graves K, Kestenbaum T & Kalivas J. Hereditary acrodermatitis enteropathica in an adult. Archives of Dermatology 1980 116 562–564.
26.&
2. 2 McGavran MH, Unger RH & Recant L. A glucagon-secreting alpha-cell carcinoma of the pancreas. New England Journal of Medicine 1966 274 1408–1413.
3. 3 Wilkinson DS. Necrolytic migratory erythema with carcinoma of the pancreas. Transactions of the St John’s Hospital Dermatological Society 1973 59 244–250.
4. 4 Wilkinson DS. Necrolytic migratory erythema with pancreatic carcinoma. Proceedings of the Royal Society of Medicine 1971 64 1197.
5. 5 Wermers RA, Fatourechi V, Wynne AG, Kvols LK & Lloyd RV. The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine 1996 75 53–63.
6. 6 Edney JA, Hofmann S, Thompson JS & Kessinger A. Glucagonoma syndrome is an underdiagnosed clinical entity. American Journal of Surgery 1990 160 625–628.
7. 7 Wermers RA, Fatourechi V & Kvols LK. Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clinic Proceedings 1996 71 1030–1038.
8. 8 Akerstrom G, Hessman O & Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Archives of Surgery 2002 386 558–569.
9. 9 Geerdink E, Van der Luijt RB & Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? European Journal of Endocrinology 2003 149 577–582.
10. 10 Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocrine Reviews 1981 2 347–361.
11. 11 Rosenberg PM & Goldfinger SE. Glucagonoma and the glucagonoma syndrome. In UptoDate 2004 online 11.3.
12. 12 Nightingale KJ, Davies MG & Kingsnorth AN. Glucagonoma syndrome: survival 24 years following diagnosis. Digestive Surgery 1999 16 68–71.
13. 13 Altimari AF, Bhoopalam N, O’Dorsio T, Lange CL, Sandberg L & Prinz RA. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Surgery 1986 100 989–996.
14. 14 Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO &Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa,
15. and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003 21 2689–2696.
16. 15 Alexander EK, Robinson M, Staniec M & Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clinical Endocrinology 2002 57 827–831.
17. 16 Bewley AP, Ross JS, Bunker CB & Staughton RC. Successful treatment of a patient with octreotide-resistant necrolytic migratory erythema. British Journal of Dermatology 1996 134 1101–1104.
18. 17 Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. American Journal of the Medical Sciences 2001 321 306–320.
19. 18 Binnick AN, Spencer SK, Dennison WL Jr & Horton ES. Glucagonoma syndrome. Report of two cases and literature review. Archives of Dermatology 1977 113 749–754.
20. 19 Haneke E. Acquired zinc deficiency mimicking glucagonoma dermatitis. Histology and electron microscopy. Zeitschrift fur Hautkrankheiten 1984 59 902–908.
21. 20 Hoitsma HF, Cuesta MA, Starink TM, Uttendorfsky-van der Putten HJ & van der Veen EA. Zinc deficiency syndrome versus glucagonoma syndrome. Archivum Chirurgicum Neerlandicum 1979 31 131–140.
22. 21 El Darouti M & Abu eE. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. International Journal of Dermatology 1996 35 252–256.
23. 22 Hendricks WM. Pellagra and pellagra like dermatoses: etiology, differential diagnosis, dermatopathology, and treatment. Seminars in Dermatology 1991 10 282–292.
24. 23 Stratigos JD & Katsambas AD. Pellagra: ‘A reappraisal’. Acta Vitaminologica et Enzymologica 1982 4 115–121.
25. 24 Graves K, Kestenbaum T & Kalivas J. Hereditary acrodermatitis enteropathica in an adult. Archives of Dermatology 1980 116 562–564.
26.&
Comentarios
Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024